Strategies for MMP inhibition in cancer: innovations for the post-trial era
Top Cited Papers
- 1 September 2002
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 2 (9) , 657-672
- https://doi.org/10.1038/nrc884
Abstract
For more than two decades, the view that tumour-associated matrix metalloproteinases (MMPs) were required for peritumour tissue degradation and metastasis dominated the drive to develop MMP inhibitors as anticancer therapeutics. Until recently, clinical trials with MMP inhibitors have yielded disappointing results, highlighting the need for better insight into the mechanisms by which this growing family of multifunctional enzymes contribute to tumour growth. It is now recognized that MMP activity is tightly regulated at several levels, providing new avenues for blocking these enzymes. What are the different approaches that can be used to target MMPs, and which of these might lead to new therapeutic strategies for cancer?Keywords
This publication has 125 references indexed in Scilit:
- Substrate Binding of Gelatinase B Induces Its Enzymatic Activity in the Presence of Intact PropeptideJournal of Biological Chemistry, 2002
- Membrane Type 1 Matrix Metalloproteinase Regulates Cellular Invasiveness and Survival in Cutaneous Epidermal CellsJournal of Investigative Dermatology, 2002
- Complex roles of tissue inhibitors of metalloproteinases in cancerOncogene, 2002
- A Novel Negative Regulatory Element in the Human Collagenase-3 Proximal Promoter RegionBiochemical and Biophysical Research Communications, 2002
- New functions for the matrix metalloproteinases in cancer progressionNature Reviews Cancer, 2002
- Scaling down imaging: molecular mapping of cancer in miceNature Reviews Cancer, 2002
- Malolactomycin D, a potent inhibitor of transcription controlled by the Ras responsive element, inhibits Ras-mediated transformation activity with suppression of MMP-1 and MMP-9 in NIH3T3 cellsOncogene, 2001
- Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTENOncogene, 2001
- Tissue Inhibitor of Metalloproteinase (TIMP)-2 Acts Synergistically with Synthetic Matrix Metalloproteinase (MMP) Inhibitors but Not with TIMP-4 to Enhance the (Membrane Type 1)-MMP-dependent Activation of Pro-MMP-2Journal of Biological Chemistry, 2000
- Repression of tissue inhibitor of matrix metalloproteinase expression by all‐trans‐retinoic acid in rat bone cell populations: Comparison with transforming growth factor‐βT1Journal of Cellular Physiology, 1995